

# Cyclic GMP Balance Is Critical for Malaria Parasite Transmission from the Mosquito to the Mammalian Host

Viswanathan Lakshmanan,<sup>a</sup> Matthew E. Fishbaugher,<sup>a</sup> Bob Morrison,<sup>a</sup> Michael Baldwin,<sup>a</sup> Michael Macarulay,<sup>a</sup> Ashley M. Vaughan,<sup>a</sup> Sebastian A. Mikolajczak,<sup>a</sup> Stefan H. I. Kappe<sup>a,b</sup>

Seattle Biomedical Research Institute (Seattle BioMed), Seattle, Washington, USA<sup>a</sup>; Department of Global Health, University of Washington, Seattle, Washington, USA<sup>b</sup>

**ABSTRACT** Transmission of malaria occurs during *Anopheles* mosquito vector blood meals, when *Plasmodium* sporozoites that have invaded the mosquito salivary glands are delivered to the mammalian host. Sporozoites display a unique form of motility that is essential for their movement across cellular host barriers and invasion of hepatocytes. While the molecular machinery powering motility and invasion is increasingly well defined, the signaling events that control these essential parasite activities have not been clearly delineated. Here, we identify a phosphodiesterase (*PDE* $\gamma$ ) in *Plasmodium*, a regulator of signaling through cyclic nucleotide second messengers. Reverse transcriptase PCR (RT-PCR) analysis and epitope tagging of endogenous *PDE* $\gamma$  detected its expression in blood stages and sporozoites of *Plasmodium yoelii*. Deletion of *PDE* $\gamma$  (*pdey*<sup>-</sup>) rendered sporozoites nonmotile, and they failed to invade the mosquito salivary glands. Consequently, *PDE* $\gamma$  deletion completely blocked parasite transmission by mosquito bite. Strikingly, *pdey*<sup>-</sup> sporozoites showed dramatically elevated levels of cyclic GMP (cGMP), indicating that a perturbation in cyclic nucleotide balance is involved in the observed phenotypic defects. Transcriptome sequencing (RNA-Seq) analysis of *pdey*<sup>-</sup> sporozoites revealed reduced transcript abundance of genes that encode key components of the motility and invasion apparatus. Our data reveal a crucial role for *PDE* $\gamma$  in maintaining the cyclic nucleotide balance in the malaria parasite sporozoite stage, which in turn is essential for parasite transmission from mosquito to mammal.

**IMPORTANCE** Malaria is a formidable threat to human health worldwide, and there is an urgent need to identify novel drug targets for this parasitic disease. The parasite is transmitted by mosquito bite, inoculating the host with infectious sporozoite stages. We show that cellular signaling by cyclic nucleotides is critical for transmission of the parasite from the mosquito vector to the mammalian host. Parasite phosphodiesterase  $\gamma$  is essential for maintaining cyclic nucleotide balance, and its deletion blocks transmission of sporozoites. A deeper understanding of the signaling mechanisms involved in transmission might inform the discovery of novel drugs that interrupt this essential step in the parasite life cycle.

Received 14 November 2014 Accepted 4 February 2015 Published 17 March 2015

**Citation** Lakshmanan V, Fishbaugher ME, Morrison B, Baldwin M, Macarulay M, Vaughan AM, Mikolajczak SA, Kappe SHI. 2015. Cyclic GMP balance is critical for malaria parasite transmission from the mosquito to the mammalian host. *mBio* 6(2):e02330-14. doi:10.1128/mBio.02330-14.

**Editor** Louis H. Miller, NIAID/NIH

**Copyright** © 2015 Lakshmanan et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported license](#), which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

Address correspondence to Stefan H. I. Kappe, stefan.kappe@seattlebiomed.org.

Malaria, a disease caused by *Plasmodium* parasites, is a formidable threat to human health, especially in resource-poor regions of the world (1). The complex life cycle of the malaria parasites provides numerous opportunities for points of intervention that pursue distinct goals such as treatment of disease or prevention of parasite transmission (2). Transmission of *Plasmodium* parasites is initiated in the mosquito when *Anopheles* vectors take a blood meal from an infected mammalian host that contains male and female gametocytes. The gametocytes differentiate into gametes in the mosquito midgut and undergo fertilization to form a zygote. Through a series of developmental steps, the zygote differentiates into sporozoites, which migrate from the midgut via the hemolymph and invade the mosquito salivary glands. Sporozoite motility and invasiveness are essential for successful completion of the *Plasmodium* life cycle in the mosquito as well as transmission to and infection of the mammalian host. The signaling events that regulate sporozoite motility and host cell infection have not been broadly studied on the molecular level, but if better

understood, they might provide targets for prevention of infection.

Sporozoite invasion of *Anopheles* salivary glands is mediated by specific interactions between receptors on the salivary gland epithelium and their respective ligands on the sporozoite surface (3, 4). To invade the salivary gland, sporozoites first penetrate the basal lamina and then enter epithelial cells within a parasitophorous vacuole (PV) (3), which disintegrates soon after invasion (5). Sporozoites exit the apical end of invaded epithelial cells and are released into the central secretory cavity of the gland from where they are delivered to the mammalian host during a blood meal (6). Upon delivery into the mammalian skin, sporozoites display robust motility, which is also observed *in vitro* (7). This interaction causes a spike in sporozoite intracellular levels of the cyclic nucleotide cyclic AMP (cAMP) (7). Motile sporozoites invade dermal capillaries and are transported to the liver, where they exit the blood by traversing the endothelial barrier, before productively invading and establishing infection in a hepatocyte. Sporozoite

zoite motility and infection of hepatocytes require a regulated release of micronemal proteins from the apical end of the sporozoite. This apical exocytosis is cAMP dependent (8). Thus, cyclic nucleotides play a critical role in sporozoite transmission and infection.

The cyclic nucleotides cAMP and cyclic GMP (cGMP) function as signaling second messengers downstream of surface receptor-ligand interactions by activating cAMP-dependent protein kinase (PKA) and cGMP-dependent protein kinase (PKG), respectively (9). Signaling through cAMP and cGMP is regulated by phosphodiesterases (PDEs), metal ion-dependent enzymes that hydrolyze the 3'-phosphoester bond of cAMP and cGMP (9). The *Plasmodium* genome encodes four PDEs ( $\alpha$ ,  $\beta$ ,  $\gamma$ , and  $\delta$ ), and the essentiality of PDEs (and therefore cyclic nucleotide-based signaling) in cellular homeostasis has fueled interest in PDEs as potential antimalarial drug targets (10, 11). Indeed, studies have shown that *Plasmodium* PDEs are important in a variety of cellular processes, including *P. gallinaceum* male gametocyte exflagellation (12), *P. falciparum* gametocytogenesis (13), cell cycle regulation (14), and *P. berghei* ookinete maturation (15).

Here, we show, through the creation of a *P. yoelii* PDE $\gamma$  deletion mutant, an essential role for PDE $\gamma$  in sporozoite transmission. *P. yoelii* *pdey*<sup>-</sup> sporozoites were nonmotile, failed to invade the salivary glands, and exhibited dramatically elevated levels of cGMP. These findings demonstrate a vital role for PDE $\gamma$  in maintaining the cyclic nucleotide balance in the malaria sporozoites, which is critical for parasite transmission.

## RESULTS


**PDE $\gamma$  is transcribed in blood stages and sporozoites.** *Plasmodium yoelii* PDE $\gamma$  (identifier [ID] PY17X\_1421600; gene information available on <http://plasmodb.org/plasmo/>) is predicted to be a 782-amino-acid type II membrane protein with six transmembrane domains. A search for the presence of domains using the PDE $\gamma$  sequence on Prosite (<http://prosite.expasy.org/>) predicted the protein to possess the conserved catalytic domain amino acid signature H-D-I-g-H-f-G-r-t-N-m-F for PDEs (16). To determine the stage of the *P. yoelii* life cycle during which PDE $\gamma$  is expressed, RNA was extracted from *P. yoelii* 17XNL strain mixed blood stages (BS), oocyst and salivary gland sporozoites isolated from mosquitoes, and liver samples collected from BALB/cJ mice 24 h and 44 h after injection with salivary gland sporozoites. Complementary DNA was synthesized, and reverse transcriptase PCR (RT-PCR) was performed using PDE $\gamma$  cDNA-specific primers. PDE $\gamma$  transcript was detected in mixed blood stages (BS), oocyst sporozoites, and salivary gland sporozoites (Fig. 1A). To analyze protein expression, the endogenous copy of *P. yoelii* PDE $\gamma$  was replaced with a tagged version encoding PDE $\gamma$  with four C-terminal copies of the c-Myc (EQKLISEEDL) epitope. Immunofluorescence assays showed PDE $\gamma$  expression to be low in BS (Fig. 1B) and high in salivary gland sporozoites (Fig. 1C). The expression in BS appeared internal and partially colocalized with the endoplasmic reticulum (ER) marker BiP (Fig. 1B). The protein also displayed an intracellular localization in sporozoites (Fig. 1C).

**PDE $\gamma$  deletion partially affects blood-stage growth.** To analyze whether PDE $\gamma$  is important for parasite life cycle progression, a double-crossover homologous recombination strategy was used to delete PDE $\gamma$  in *P. yoelii* (Fig. 2A). The gene was not refractory to deletion, and several clones of knockout (*pdey*<sup>-</sup>) parasites were

successfully generated, showing that PDE $\gamma$  was not essential for BS replication. Two clones of *pdey*<sup>-</sup> parasites were selected and genotyped by PCR (Fig. 2B) and Southern blotting (Fig. 2C) to confirm the purity of the clones. A BS growth assay was performed to determine whether there was a difference in the kinetics of growth between wild-type (WT) and *pdey*<sup>-</sup> parasites. Swiss Webster (SW) mice were injected intravenously (i.v.) with WT and *pdey*<sup>-</sup> clones, and parasitemia was analyzed daily by microscopic examination of Giemsa-stained thin blood smears for 20 days. Parasitemias were comparable between WT and both *pdey*<sup>-</sup> clones during the initial phase of BS growth (from days 1 through 9) (Fig. 2D). However, WT and *pdey*<sup>-</sup> parasites differed in growth kinetics from days 10 through 15. The peak average parasitemia in mice infected with WT parasites was ~16%, which was ~2-fold higher than the peak average parasitemia of ~8% in mice infected with the *pdey*<sup>-</sup> clones. During later stages of growth (day 12 onward), the *pdey*<sup>-</sup> clones were cleared from mice earlier than WT parasites (Fig. 2D). These data show that PDE $\gamma$  is not essential for BS parasite growth and replication.

**PDE $\gamma$  deletion abrogates sporozoite infection of the mosquito salivary glands.** Next, we analyzed whether there were differences in gametocytogenesis and mosquito infections between WT and *pdey*<sup>-</sup> parasites. No significant difference (data not shown) was observed. Mosquitoes were then allowed to feed on mice infected with WT or *pdey*<sup>-</sup> parasites, and oocyst sporozoites and salivary gland sporozoites were enumerated on days 10 and 14 postfeeding, respectively. No statistically significant difference was observed for the number of oocyst sporozoites per mosquito between WT (48,942  $\pm$  17,497) and *pdey*<sup>-</sup> clones c1 (36,112  $\pm$  16,521;  $P = 0.6058$  compared to WT) and c2 (32,202  $\pm$  18,200;  $P = 0.5232$  compared to WT) (Fig. 3A). In contrast, salivary gland sporozoite numbers in mosquitoes that were infected with *pdey*<sup>-</sup> clones were on average ~55-fold lower (304  $\pm$  110 for c1,  $P = 0.0144$  versus WT, and 358  $\pm$  143 for c2,  $P = 0.0146$  versus WT) than salivary gland sporozoite numbers from mosquitoes that were infected with WT parasites (18,114  $\pm$  5,233) (Fig. 3B). These data show that *pdey*<sup>-</sup> sporozoites failed to invade the salivary glands of mosquitoes.

**PDE $\gamma$  deletion blocks sporozoite transmission by mosquito bite.** Given the apparent failure of *pdey*<sup>-</sup> sporozoites to invade the mosquito salivary glands, we tested whether they were transmissible to mice through mosquito bite. An initial experiment with 20 *pdey*<sup>-</sup> sporozoite-infected mosquitoes per mouse did not result in patent BS infection in any mice (Table 1). Strikingly, no BS patency was observed even with 45 or 100 *pdey*<sup>-</sup> sporozoite-infected mosquito bites per mouse. In contrast, WT parasite-infected mosquito bites consistently caused patent BS infection in all mice (Table 1). We next set out to determine whether *pdey*<sup>-</sup> sporozoites that were associated with mosquito salivary glands could cause infection in mice when delivered intravenously. Injection of 1,000 *pdey*<sup>-</sup> salivary gland-associated sporozoites did not result in BS parasitemia in mice, whereas all mice injected with WT salivary gland sporozoites became patent, as expected (Table 2). However, injection of a higher dose of 10,000 *pdey*<sup>-</sup> salivary gland-associated sporozoites caused blood-stage patency in a fraction of the mice (~63%) around day 4. In comparison, 100% of 10,000 WT sporozoite-injected mice became patent around day 3 (Table 2). We also compared the infectivity with 10,000 WT and *pdey*<sup>-</sup> sporozoites extracted from the mosquito hemolymph by intravenous injection. Once again, only a fraction of mice (40%)




**FIG 1** Expression analysis of *P. yoelii* PDE $\gamma$  by RT-PCR and immunofluorescence assay. (A) RT-PCR for *P. yoelii* PDE $\gamma$  transcripts in mixed blood stages (mBS), oocyst sporozoites (Oo-spz), and salivary gland sporozoites (Sg-spz) of *P. yoelii* WT parasites. 18S rRNA of *P. yoelii* (Py18S) was used as a positive control. + or – indicates cDNA synthesis with or without reverse transcriptase, respectively. (B) Immunofluorescence assay of mixed blood stages stained with anti-Myc antibody and costained with antibody against either the ER marker BiP (top panel) or the parasite plasma membrane marker MSP1 (bottom panel). (C) Immunofluorescence assay of salivary gland sporozoites stained with anti-Myc antibody and costained with antibody against either the apicoplast marker ACP (top panel), sporozoite surface marker CSP (middle panel), or IMC marker TRAP (bottom panel). Nucleus was visualized using DAPI. Bars, 2.5  $\mu$ m. DIC, differential interference contrast.

injected with *pde $\gamma$* <sup>-</sup> sporozoites developed blood-stage patency, whereas 100% of mice injected with WT sporozoites became BS patent. As with salivary gland sporozoites, *pde $\gamma$* <sup>-</sup> hemolymph sporozoites caused patency with a 1-day delay compared to WT (day 4.5 for *pde $\gamma$* <sup>-</sup> sporozoites versus day 3.5 for WT sporozoites) (Table 2).

***pde $\gamma$* <sup>-</sup> salivary gland sporozoites are defective in substrate-dependent gliding motility.** We hypothesized that the failure of *pde $\gamma$* <sup>-</sup> sporozoites to invade mosquito salivary glands might be due to a defect in their motility. The average frequency of motility exhibited by WT salivary gland sporozoites was  $\sim 43\% \pm 8\%$ . Strikingly, *pde $\gamma$* <sup>-</sup> salivary gland-associated sporozoites were

nearly immotile. The percentages of sporozoites with circumsporozoite protein (CSP) trails for *pde $\gamma$* <sup>-</sup> clones were  $0.8\% \pm 0.2\%$  and  $0.4\% \pm 0.07\%$ , on average  $\sim 72$ -fold lower than those for WT salivary gland sporozoites ( $P = 0.0130$  for *pde $\gamma$* <sup>-</sup> c1 versus WT and  $P = 0.0128$  for *pde $\gamma$* <sup>-</sup> c2 versus WT) (Fig. 4A). This near lack of motility was comparable to WT oocyst sporozoites, which are known to display little motility ( $\sim 0.5\% \pm 0.1\%$ ). To more accurately compare motility of sporozoites, we collected hemolymph sporozoites from mosquitoes infected with either WT or *pde $\gamma$* <sup>-</sup> parasites. While  $\sim 21\%$  ( $20.67\% \pm 1.76\%$ ) of WT hemolymph sporozoites generated CSP trails and thus were motile, no motility was observed with *pde $\gamma$* <sup>-</sup> hemolymph sporozoites. The




**FIG 2** Deletion of *P. yoelii* *PDEγ* and characterization of *pdeγ*<sup>-</sup> parasites. (A) Schematic of the strategy for deleting *PDEγ* in *P. yoelii* 17XNL by homologous recombination using a linearized plasmid. Primers used for genotyping PCR and enzymes (B, BsrGI; S, SphI) and probe (black bar) used for Southern blotting are shown. Sizes of genomic DNA fragments distinguishing WT from knockout clones are indicated in kilobases. (B) Genotyping PCR of two *pdeγ*<sup>-</sup> clones (c1 and c2) with WT and plasmid controls. (C) Southern blotting of AflIII-digested genomic DNA from WT and two *pdeγ*<sup>-</sup> clones with a 3' probe yielded a 3.901-kb band for WT and a 1.756-kb band for the two *pdeγ*<sup>-</sup> clones, respectively. (D) Comparison of asexual blood-stage growth rates between WT and *pdeγ*<sup>-</sup> sporozoites as measured by increase in parasitemia in infected mice over time. Parasitemias are plotted as means  $\pm$  standard deviations.

percentage of *pdeγ*<sup>-</sup> hemolymph sporozoites with CSP trails was  $0.35\% \pm 0.08\%$ , on average ~60-fold lower than ( $P = 0.0073$  versus WT) that of WT hemolymph sporozoites (Fig. 4A).

***pdeγ*<sup>-</sup> sporozoites exhibit elevated cGMP levels.** To address whether cyclic nucleotide levels were perturbed in *pdeγ*<sup>-</sup> parasites, cGMP concentration was measured in WT and *pdeγ*<sup>-</sup> oocyst sporozoites. The concentration of cGMP was found to be ~18-fold higher ( $P < 0.0001$ ) in *pdeγ*<sup>-</sup> sporozoites ( $72 \pm 12$  pmol/ml) than in WT parasites ( $4 \pm 0.1$  pmol/ml) (Fig. 4B). In order to assess whether inhibiting PDE would have an effect on the motility of salivary gland sporozoites, we used zaprinast (an inhibitor of PDE that hydrolyzes cGMP) in the motility assay. At 250, 500, and 1,000  $\mu$ M, zaprinast caused 28, 37, and 43% decreases in sporozoite motility, respectively, compared to control (Fig. 4C). Together, the data suggest that *PDEγ* regulates cyclic GMP levels, which in turn regulate signaling events that control sporozoite motility.

**Transcript abundance for proteins involved in motility and invasion is downregulated in *pdeγ*<sup>-</sup> sporozoites.** Given the in-

volvement of PDEs in regulating signaling and gene expression, we performed RNA-Seq analysis to analyze the effect of *PDEγ* deletion on transcript abundance in sporozoites. RNA was extracted from day 10 WT and *pdeγ*<sup>-</sup> oocyst sporozoites (three independent mosquito infections were used to produce sporozoites that were pooled for RNA-Seq) that had been purified using DE52 columns to remove mosquito debris (17). Differentially expressed genes were determined (at least 2-fold, with Bonferroni-corrected  $P$  value of  $< 0.05$ ) (Fig. 5A). As expected, no *PDEγ* transcript was detected in *pdeγ*<sup>-</sup> sporozoites (Fig. 5B). Interestingly, expression analysis of other cyclic nucleotide PDEs in *pdeγ*<sup>-</sup> sporozoites showed upregulation of *PDEδ* and *PDEβ*, respectively (as determined by comparing normalized RPKM [read per kilobase per million] values), whereas *PDEα* levels were relatively unaffected (Fig. 5B). Given the *pdeγ*<sup>-</sup> sporozoite defects in gliding motility and mosquito salivary gland invasion as well as mammalian host liver infection, we also analyzed transcript levels of genes known to be involved in sporozoite motility and invasion. We found transcripts for *TRAP* and *CSP* to be downregulated ~15-fold and ~5-



**FIG 3** Quantification of oocyst sporozoites and salivary gland sporozoites. (A) Oocyst sporozoite numbers from mosquitoes infected with WT or *pdeγ*<sup>-</sup> clones on day 10 after infectious blood meal. (B) Salivary gland sporozoite numbers from mosquitoes infected with WT or *pdeγ*<sup>-</sup> clones on day 14 after infectious blood meal. Both oocyst and salivary gland sporozoite numbers were determined multiple times with independent infections. Bar graphs represent means ± standard errors of the means. Unpaired *t* test with Welch's correction was used for statistical analysis.

fold, respectively (Fig. 5C). Other transcripts of relevance that were downregulated in *pdeγ*<sup>-</sup> sporozoites included *UIS4* (~26-fold), *Puf2* (~19-fold), and *SAP1* (~18-fold) (Fig. 5D), *TREP* (~4.5-fold), *GEST* (~16-fold), and *CelTOS* (~20-fold) (Fig. 5E). RPKM values for all transcripts are shown in Table S1 in the supplemental material.

## DISCUSSION

Previous studies have indicated the importance of cyclic nucleotide-based signaling in *Plasmodium* parasites, including a role of cAMP in gametocyte biology (12, 13, 18), asexual blood-stage cell cycle synchronization (14), and merozoite egress (19). In this report, we have demonstrated that *P. yoelii* *PDEγ* is a cGMP-capable phosphodiesterase which is critical for maintaining cGMP balance in sporozoites. Deleting *PDEγ* dramatically increased cGMP levels, rendering sporozoites immotile and unable to invade the mosquito salivary glands. Consequently, the *pdeγ*<sup>-</sup> parasites failed to transmit to the mammalian host by mosquito bite.

*PDEγ* transcripts were detectable by RT-PCR in blood stages, oocyst sporozoites, and salivary gland sporozoites. A previous proteomic analysis detected *P. yoelii* *PDEγ* in whole-cell lysates of WT salivary gland sporozoites (20). Expression was demonstrated here by immunofluorescence analysis of Myc-tagged *PDEγ* salivary gland sporozoites, revealing intracellular *PDEγ* expression with a granular distribution. *PDEγ* also showed weak expression in asexual blood stages. Deletion of *PDEγ* reduced peak blood-stage parasitemia, which suggests a nonessential role of *PDEγ* during blood-stage growth/replication. It is possible that other PDEs partially compensated for the loss of *PDEγ*, enabling *pdeγ*<sup>-</sup> parasites to maintain asexual blood-stage growth. In this context, it is

of note that *P. falciparum* *PDEγ* can also be deleted, but an effect on blood-stage growth was not reported (21). In *P. falciparum* blood stages, *PDEα* and *PDEβ* are the predominant *PDE* transcripts (22), but the essentiality for blood-stage replication has been determined only for *PDEα*. *PDEδ* is not essential for *P. falciparum* (21) and *P. berghei* (15) blood-stage replication. Other *PDE* family members may complement single *PDE* gene deletions, although no changes in expression levels of PDEs were observed upon deleting *PDEα* in *P. falciparum* (22).

We found that deleting *P. yoelii* *PDEγ* did not affect gametocytogenesis, exflagellation of male gametes, oocyst development, and oocyst sporozoite differentiation. This observation is in agreement with an earlier report in which *P. berghei* *PDEγ* deletion mutants were viable with no discernible phenotype up to and including the oocyst stage (15). In stark contrast to normal oocyst sporozoite development, *pdeγ*<sup>-</sup> sporozoite salivary gland infection was severely affected, suggesting that *PDEγ* is essential for parasite entry into the glands. In addition, *pdeγ*<sup>-</sup> sporozoites failed to transmit to the mammalian host via mosquito bite. Interestingly, artificial transmission by intravenous injection of large numbers of *pdeγ*<sup>-</sup> hemolymph or salivary gland sporozoites resulted in blood-stage patency in a fraction of challenged mice, but the mice that became infected did so with delayed patency. A similar severe-infection phenotype was previously observed with *P. berghei* *trap*<sup>-</sup> sporozoites, and the reason for a fraction of animals becoming patent was attributed to stochastic events such as uptake by host cells of noninvasive sporozoites (23). Similar events may explain the breakthrough infections observed with *pdeγ*<sup>-</sup> sporozoites.

It has been hypothesized that plasmodial PDEs are structurally and catalytically more adept at metabolizing cGMP rather than cAMP (24), and biochemical assays have indeed demonstrated that *Plasmodium* *PDEα* and *PDEδ* have a specificity for cGMP (22, 25), whereas *PDEβ* likely has dual specificity (22, 25). The cyclic nucleotide specificity of *PDEγ*, however, has not previously been defined, and we surmised that cyclic nucleotide levels in *pdeγ*<sup>-</sup> sporozoites were perturbed. Indeed, cGMP levels in *P. yoelii* *pdeγ*<sup>-</sup> sporozoites were dramatically elevated compared to WT parasites. These data indicate that *PDEγ* has strong capability for hydrolyzing cGMP. Inhibition of sporozoite motility by zaprinast, a cGMP-specific PDE inhibitor, is in agreement with this notion.

Cyclic GMP is a key regulator of several physiological pro-

**TABLE 1** Infections of BALB/c mice with WT or *pdeγ*<sup>-</sup> parasites via mosquito bite

No. of mosquitoes/mouse	Genotype	No. of mice/no. patent
~20	WT	3/3
	<i>pdeγ</i> <sup>-</sup> c1	3/0
	<i>pdeγ</i> <sup>-</sup> c2	3/0
~45	WT	3/3
	<i>pdeγ</i> <sup>-</sup> c1	3/0
	<i>pdeγ</i> <sup>-</sup> c2	3/0
~100	WT	5/3
	<i>pdeγ</i> <sup>-</sup> c1	5/0
	<i>pdeγ</i> <sup>-</sup> c2	5/0

**TABLE 2** Infections of BALB/c mice with WT or *pdey*<sup>-</sup> parasites via intravenous sporozoite injections


Sporozoite dose	Sporozoite source	Genotype	No. of mice/no. patent	No. of days to patency
1000	SG	WT	6/6	4.3
	SG	<i>pdey</i> <sup>-</sup> c1	6/0	NP
	SG	<i>pdey</i> <sup>-</sup> c2	6/0	NP
10,000	HL	WT	5/5	3.5
	HL	<i>pdey</i> <sup>-</sup>	5/2	4.5
	SG	WT	6/6	3
	SG	<i>pdey</i> <sup>-</sup>	8/5	4.2

<sup>a</sup> Abbreviations: HL, hemolymph; SG, salivary gland; NP, not patent.


cesses, including regulation of gene expression at both transcriptional and posttranscriptional levels (26). The latter includes splicing, mRNA stability, and translation (26). By dampening cyclic nucleotide signal transduction, PDEs control cyclic nucleotide-based regulation of gene expression (26–28). Thus, we assessed whether the perturbation of cGMP levels in *pdey*<sup>-</sup> oocyst sporozoites affected gene expression on a global level by RNA-Seq comparisons of WT and *pdey*<sup>-</sup> sporozoites. We initially examined PDE transcription and found that *PDEδ* and *PDEβ* transcript levels were upregulated in *pdey*<sup>-</sup> sporozoites although *PDEα* transcript levels were unaffected. In light of the strong defect in salivary gland invasion, we next determined whether deleting *PDEγ* altered the levels of transcripts encoding proteins involved in this process and interestingly found a downregulation of TRAP, CSP, and TREP transcripts in *pdey*<sup>-</sup> sporozoites. This downregulation could be the functional cause for the lack of *pdey*<sup>-</sup> sporozoite

invasion into salivary glands. TRAP, CSP, and TREP are also important for sporozoite motility (29). Thus, reduction of transcript abundance for these genes in *pdey*<sup>-</sup> sporozoites would affect motility. Indeed, *pdey*<sup>-</sup> sporozoites were defective in substrate-dependent gliding motility and CSP shedding. These data are in agreement with the roles of TRAP, CSP, and TREP and point to a critical role for *PDEγ* in sporozoite invasion and motility via regulating gene expression for key sporozoite invasion and motility-related proteins.

Interestingly, transcript abundance for *UIS4*, *Puf2*, and *SAP1*, which encode proteins that are critical for sporozoite infectivity of the mammalian host, was also strongly diminished in *pdey*<sup>-</sup> sporozoites. *UIS4* is expressed in infective sporozoites and liver stages, and deleting *UIS4* causes impaired liver-stage development (30). Deleting *Puf2* results in premature initiation of sporozoite transformation into liver stages in mosquito salivary glands and



**FIG 4** Sporozoite motility assay and quantification of cGMP level in sporozoites. (A) Percentages of day 10 WT oocyst (MG), day 12 WT and *pdey*<sup>-</sup> hemolymph (HL), and day 14 WT and *pdey*<sup>-</sup> salivary gland (SG) sporozoites to assess substrate-dependent motility by deposition of CSP trails. Motility was assessed multiple times with independent sporozoite preparations. (B) Acetylated cGMP levels in extracts prepared from day 10 WT and *pdey*<sup>-</sup> oocyst sporozoites. Bar graphs represent means  $\pm$  standard errors of the means. Unpaired *t* test with Welch's correction was used for statistical analysis. (C) Percentages of day 10 WT oocyst (MG NT) and day 14 salivary gland WT (SG NT) salivary gland sporozoites to assess substrate-dependent motility compared to day 14 salivary gland sporozoites treated with zaprinast (ZAP), a PDE inhibitor at different concentrations. SG DMSO, salivary gland sporozoites treated with dimethyl sulfoxide (DMSO) as a control for zaprinast solvent.



**FIG 5** Comparison of transcript abundance (shown as reads per kilobase per million [RPKM] values) for representative genes in *P. yoelii* WT and  $pde\gamma^-$  oocyst sporozoites. (A) MA plot (or scatter plot) of comparative expression of 6,053 *P. yoelii* genes from  $PDE\gamma^-$  and wild-type (WT) samples. Significantly differentially expressed genes (at least 2-fold, with Bonferroni-corrected  $P$  value of  $<0.05$ ) are highlighted in color: 428 genes upregulated in  $PDE\gamma^-$  sporozoites shown in red, 271 genes upregulated in WT shown in green. (B to E) Comparisons of transcript abundances:  $PDE\alpha$ ,  $PDE\beta$ ,  $PDE\gamma$ , and  $PDE\delta$  (B); TRAP and CSP (C); UIS4, Puf2, and SAP1 (D); and TREP, GEST, and CelTOS (E).

reduced sporozoite gliding motility, cell traversal, and hepatocyte infectivity (31). *P. yoelii* SAP1 is essential for a productive liver-stage infection, and deleting SAP1 causes the downregulation of several sporozoite transcripts, including UIS4 and Puf2 but not CSP and TRAP (32). Both SAP1 and Puf2 are involved in the

storage and protection of mRNAs that code for proteins critical in mammalian host infection. We showed that deleting *P. yoelii*  $PDE\gamma$  leads to perturbed cGMP levels in sporozoites. Given the role of cGMP in regulating gene expression at the transcriptional and posttranscriptional levels (26), uninhibited signaling down-

stream of cGMP in *pdey*<sup>-</sup> sporozoites could explain the perturbations and phenotypes that we observed.

In light of the elevated cGMP levels and the resulting lack of motility of *pdey*<sup>-</sup> sporozoites, it is noteworthy that the interaction of WT sporozoites with albumin causes a spike in intracellular levels of cAMP (and Ca<sup>2+</sup>) and the release of the micronemal proteins TRAP and CSP, necessary for motility (7). If cAMP formation is inhibited, however, motility is lost (7). Thus, it is possible that cAMP- and cGMP-based signaling pathways perform opposing functions in the sporozoite and that maintaining a balance between cAMP and cGMP levels is critical for sporozoite motility and infectivity. Further experiments are required to assess whether cAMP levels are perturbed in *pdey*<sup>-</sup> sporozoites and whether there is cross talk between cAMP and cGMP signaling.

Our data indicate that PDE $\gamma$  plays a critical role in maintaining cGMP balance in sporozoites. Skewing this balance causes down-regulation of transcripts that code for proteins involved in sporozoite motility and invasion. Currently, there is a knowledge gap concerning the specific parasite-host interactions that activate downstream cyclic nucleotide/PDE-dependent signaling pathways. Further experiments are required to understand how cGMP-mediated signaling and PDE activity translate external signals into intracellular gene regulatory responses in malaria parasites.

## MATERIALS AND METHODS

**Experimental animals and parasite production.** Six- to 8-week-old female Swiss Webster (SW) mice from Harlan (Indianapolis, IN) were used for production of transgenic parasites and for parasite life cycle maintenance. Six- to 8-week-old female BALB/cJ mice from the Jackson Laboratory (Bar Harbor, ME) were used for assessment of parasite infectivity. *P. yoelii* 17XNL nonlethal WT and transgenic parasites were cycled between SW mice and *Anopheles stephensi* mosquitoes. Infected mosquitoes were maintained on sugar water at 24°C and 70% humidity. This study was carried out in accordance with the recommendations in the *Guide for the Care and Use of Laboratory Animals* of the National Institutes of Health (42). The Seattle Biomedical Research Institute has an OLAW Animal Welfare Assurance (A3640-01). The protocol was approved by Seattle BioMed's Institutional Animal Care and Use Committee.

**Generation of *pdey*<sup>-</sup> parasites.** Gene targeting constructs for transgenic parasite production were designed as previously described (33). *P. yoelii* 17XNL genomic DNA was used to amplify a 658-bp fragment of the 3' untranslated region (UTR) using oligonucleotide primers 5' GCG AGCTCGGTACCTATGCGTATAATATTATATGAATAAGAC (sense) and 5' CATGATATATAACCCTGCAGGTTAACTTGTTTTTATGGAAATTTAAACC (antisense) and a 566-bp fragment of the 5' UTR with primers 5' CATAAAAACAAGTTAACCTGCAGGGTTATATATCATGG AATTTTCGTTGCAC (sense) and 5' ATGCGGCCGCTATCGTTTGACA CGAATAAATTTAATCG (antisense) of *P. yoelii* PDE $\gamma$  (*PyPDE $\gamma$* ). The two PCR products were fused by sequence overlap extension PCR (SOE PCR) (33). The SOE PCR product was cloned into pCR-Blunt (Life Technologies), sequenced, digested with KpnI and NotI, gel purified using a gel extraction kit (Qiagen), and cloned into a modified version of plasmid pL0005 (MR4: MRA-774) containing GFPmut2 under the control of the constitutive *P. berghei* elongation factor 1 alpha promoter. The final plasmid was linearized with SbfI. Transfection of *P. yoelii* 17XNL parasites using the Amaxa Nucleofector device (Lonza) and selection of resistant parasites were conducted as previously described (34).

**Genotyping of transgenic parasites.** Transgenic parasites were cloned by limiting dilution infection of female SW mice, and two independent clones were selected for phenotypic analysis. The presence of transgenic parasites was assessed by genotyping PCR using primers 5' TTCAATAT TTGTAGTTGATAGTTTTTGC (sense) and 5' AAACATGTTTGTA

CATTTGTTAATATC (antisense) for the 5' end and primers 5' TAACC CATTATTTGATCGAAAAGCTC (sense) and 5' GCAAAAATGCTCAA ACCAAACATTGG (antisense) for the 3' end of the WT locus, primers 5' CAACTCCAGTGAAAAGTTCTTCTCC (sense) and 5' AAACATGTT GTAAACATTTGTTAATATC (antisense) for the 5' end and primers 5' TAAGTACAAATTTGAAGTATATGAGAAG (sense) and 5' AAACGAA AAACATTTATAAAGTATATACG (antisense) for the 3' end of the *pdey*<sup>-</sup> locus, and primers 5' GCGAGCTCGGTACCTATGCGTATAATA TTATATGAATAAGAC (sense) and 5' ATGCGGCCGCTATCGTTGACACGAATAAATTTAATCG (antisense) for the episomal plasmid. Southern blotting for the PDE locus was performed by hybridizing BsrGI-SphI-digested genomic DNA from WT and *pdey*<sup>-</sup> clones with a 3' probe generated using primers 5' GCGAGCTCGGTACCTATGCGTATAATAT TATATGAATAAGAC (sense) and 5' CATGATATATAACCCTGCAGG TTAACCTGTTTTTATGGAAATTTAAACC (antisense). Digested DNA was run on a 0.7% Tris-acetate-EDTA agarose gel at 55 V and transferred to a Hybond-N membrane (Amersham, GE Healthcare Life Sciences, Pittsburgh, PA) in 20 $\times$  SSC (1 $\times$  SSC is 0.15 M NaCl plus 0.015 M sodium citrate) overnight at room temperature. DNA was UV cross-linked to the membrane and hybridized with digoxigenin (DIG)-labeled probes prepared using the DIG kit (Roche Diagnostics, Indianapolis, IN).

**Blood-stage growth assay.** Groups of three SW mice each were infected intravenously with 1  $\times$  10<sup>6</sup> infected red blood cells (iRBCs) of WT and two *pdey*<sup>-</sup> clones. Blood smears were prepared and stained with Giemsa stain, and parasitemia was checked each day for 20 days.

**Reverse transcriptase PCR (RT-PCR).** Samples for RNA extraction were stored in TRIzol (Life Technologies) at -80°C until used. Total RNA was extracted using the Direct-zol MiniPrep kit (Zymo Research, Irvine, CA) according to the manufacturer's instructions. Complementary DNA synthesis was performed using the QuantiTect reverse transcription kit (Qiagen) according to the manufacturer's instructions. PCR cycling conditions used for amplification of cDNA were 92°C for 30 s for DNA denaturation, 54°C for 30 s for primer annealing, and 62°C for 1 min for extension (35 cycles). *P. yoelii* PDE $\gamma$  was amplified using primers 5' TTA AGGAAAAAGACGAAGAACTCTG (sense) and 5' GGATCTATTACC AATTTGTGTAACG (antisense). *P. yoelii* 18S rRNA was amplified using primers 5' GGGGATTGGTTTTGACGTTTTTGCG (sense) and 5' AAGCATTAAATAAAGCGAATACATCCTTAT (antisense).

**Epitope tagging.** The tagging construct was designed to replace the endogenous locus with the tagged version of *P. yoelii* PDE $\gamma$  by double-crossover homologous recombination. *P. yoelii* 17XNL genomic DNA was used to amplify a 669-bp fragment of the 3' end of the coding sequence without the stop codon of *P. yoelii* PDE $\gamma$  using oligonucleotide primers 5' GATAAATGACAAATTTACGGCCGAATCAATATTAGAGA ATTATCATTGCTC (sense) and 5' ATACTAGTTAATTTATATATATT AAGATTTGGTGCATAAAC (antisense) and a 630-bp fragment of the 3' UTR with primers 5' ATCCGCGGCATGGAAAATTGTTTATGCCA AATC (sense) and 5' CTAATATTGATTCCGCCGTAATTTGTCATTT ATCATATATACATG (antisense). The two PCR products were fused by sequence overlap extension PCR (SOE PCR) (33). The SOE PCR product was cloned into pCR-Blunt (Life Technologies), sequenced, digested with SacII and SpeI, gel purified using a gel extraction kit (Qiagen), and cloned into a modified version of plasmid pL0005 (MR4: MRA-774), pL0005-cMyc, which allowed tagging of proteins with a C-terminal quadruple Myc (4 $\times$  Myc) tag. The final plasmid was linearized with EagI. Transfection of *P. yoelii* 17XNL parasites and selection of resistant parasites were conducted as previously described (33).

**Immunofluorescence assays.** Oocyst or salivary gland sporozoites were isolated by microdissection and fixed with 4% paraformaldehyde (PFA) for 15 min. Sporozoites were washed twice with phosphate-buffered saline (PBS), permeabilized with 0.1% Triton X-100 in PBS for 15 min, and blocked with 3% bovine serum albumin (BSA) in PBS for 1 h. Sporozoites were stained with antibodies against BiP, acyl carrier protein (ACP), CSP (2F6), TRAP, or c-Myc (SC-789; Santa Cruz) for 1 h. Sporozoites were washed and incubated with fluorophore-conjugated second-



ary antibodies specific to rabbit or mouse IgG for 1 h. Sporozoites were then washed and stained for the DNA with DAPI (4',6-diamidino-2-phenylindole) for 5 min. Sporozoites were applied to glass slides and mounted with antifade reagent (Vectashield; Vector Laboratories). All steps were performed at room temperature. Images were acquired using an Olympus IX70 DeltaVision microscope equipped with deconvolution software.

**Analysis of sporozoite motility.** Sporozoites were tested for *in vitro* substrate-dependent motility using coverslips precoated with anti-circumsporozoite protein (anti-CSP) antibodies. Motility was assessed by determining the percentage of sporozoites that were able to generate CSP trails. For zaprinast inhibitor (Sigma) experiments, the inhibitor was resuspended in dimethyl sulfoxide (DMSO) (Sigma) and added during the gliding assay.

**Analysis of sporozoite infectivity by mosquito bite infection.** Groups of BALB/cJ mice (3 to 5 per group) were anesthetized and individually exposed to the bites of 20 to 100 WT or *pdey*<sup>-</sup> sporozoite-infected mosquitoes. Mosquitoes were allowed to feed for a total of 7.5 min, with rotation of the mice between five mosquito cages every 1.5 min. Before performing mosquito bite infections, salivary glands of mosquitoes were checked for the presence of sporozoites. The time to blood-stage patency was determined microscopically by Giemsa-stained thin blood smears. All mice were checked either until patency was observed or for 14 days, whichever was earlier.

**Analysis of sporozoite infectivity by i.v. injection.** Sporozoites were isolated by microdissecting mosquito salivary glands 14 or 15 days after the infectious blood meal. Sporozoites were injected intravenously (i.v.) into the tail vein of BALB/cJ mice. The time to blood-stage patency (defined as >1 infected erythrocyte/10,000 erythrocytes) was determined microscopically using Giemsa-stained thin blood smears. All mice were checked either until patency was observed or for 14 days, whichever was earlier.

**cGMP assay.** The assay for determining cGMP levels in sporozoites was performed using the cyclic GMP enzyme immunoassay (EIA) kit (catalog no. 581021; Cayman Chemical) per the manufacturer's instructions. Sporozoites for the assay were purified on an Accudenz gradient to eliminate mosquito debris (17), and sporozoite extracts were prepared by two rounds of freezing on dry ice-ethanol, thawing on ice, and passaging through a 28-gauge needle from the same number of sporozoites for each line. Equal volumes of extract from WT and *pdey*<sup>-</sup> sporozoites were used to assay for cGMP.

**Transcription abundance from RNA-Seq sequencing data.** Raw FASTQ read data were processed using in-house R package DuffyNGS as originally described (35). Briefly, raw reads pass through a 3-stage alignment pipeline: (i) a prealignment stage to filter out unwanted transcripts, such as rRNA, mitochondrial RNA, albumin, and globin; (ii) a main genomic alignment stage against the genome(s) of interest; and (iii) a splice junction alignment stage against an index of standard and alternative exon splice junctions. All alignments were performed with Bowtie2 (36), using the command line option "very-sensitive." BAM files from stages 2 and 3 are combined into read depth wiggle tracks that record both uniquely mapped and multiply mapped reads to each of the forward and reverse strands of the genome(s) at single-nucleotide resolution. Multiply mapped reads are prorated over all highest-quality aligned locations. Gene transcript abundance is then measured by summing total reads landing inside annotated gene boundaries, expressed as both RPKM (37) and raw read counts. Two stringencies of gene abundance are provided using all aligned reads and by just counting uniquely aligned reads.

**Differential transcription.** To minimize biases from the choice of algorithm for calling differential expressed (DE) genes, a panel of 5 DE tools was utilized. They included (i) RoundRobin (in-house); (ii) RankProduct (38); (iii) significance analysis of microarrays (SAM) (39); (iv) EdgeR (40); and (v) DESeq (41) (see Table S1 in the supplemental material). Each DE tool was called with appropriate default parameters and operated on the same set of transcription results, using RPKM abundance

units for RoundRobin, RankProduct, and SAM and raw read count abundance units for DESeq and EdgeR. All 5 DE results were then synthesized, by combining gene DE rank positions across all 5 DE tools. Specifically, a gene's rank position in all 5 results was averaged, using a generalized mean to the 1/2 power, to yield the gene's final net rank position. Each DE tool's explicit measurements of differential expression (fold change) and significance (*P* value) were similarly combined via appropriate averaging (arithmetic and geometric mean, respectively). The final DE result was sorted by gene net rank position such that the top genes were those found in common by all DE tools.

## SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <http://mbio.asm.org/lookup/suppl/doi:10.1128/mBio.02330-14/-/DCSupplemental>.

Table S1, XLSX file, 4.4 MB.

## ACKNOWLEDGMENTS

This research was funded by a grant from the Foundation for the National Institutes of Health through the Grand Challenges in Global Health Initiative (grant 1481).

The authors declare no conflict of interest.

## REFERENCES

1. World Health Organization, Malaria Control Department. 2013. Malaria report 2013. World Health Organization, Geneva, Switzerland. [http://www.who.int/malaria/publications/world\\_malaria\\_report\\_2013/en](http://www.who.int/malaria/publications/world_malaria_report_2013/en).
2. Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, Collins FH, Duffy PE. 2008. Malaria: progress, perils, and prospects for eradication. *J Clin Invest* 118:1266–1276. <http://dx.doi.org/10.1172/JCI33996>.
3. Ghosh AK, Jacobs-Lorena M. 2009. Plasmodium sporozoite invasion of the mosquito salivary gland. *Curr Opin Microbiol* 12:394–400. <http://dx.doi.org/10.1016/j.mib.2009.06.010>.
4. Wang J, Zhang Y, Zhao YO, Li MW, Zhang L, Dragovic S, Abraham NM, Fikrig E. 2013. Anopheles gambiae circumsporozoite protein-binding protein facilitates plasmodium infection of mosquito salivary glands. *J Infect Dis* 208:1161–1169. <http://dx.doi.org/10.1093/infdis/jit284>.
5. Rodriguez MH, Hernández-Hernández FDL. 2004. Insect-malaria parasites interactions: the salivary gland. *Insect Biochem Mol Biol* 34:615–624. <http://dx.doi.org/10.1016/j.ibmb.2004.03.014>.
6. Pimenta PF, Touray M, Miller L. 1994. The journey of malaria sporozoites in the mosquito salivary gland. *J Eukaryot Microbiol* 41:608–624. <http://dx.doi.org/10.1111/j.1550-7408.1994.tb01523.x>.
7. Kebaier C, Vanderberg JP. 2010. Initiation of plasmodium sporozoite motility by albumin is associated with induction of intracellular signalling. *Int J Parasitol* 40:25–33. <http://dx.doi.org/10.1016/j.ijpara.2009.06.011>.
8. Ono T, Cabrita-Santos L, Leitao R, Bettiol E, Purcell LA, Diaz-Pulido O, Andrews LB, Tadakuma T, Bhanot P, Mota MM, Rodriguez A. 2008. Adenylyl cyclase alpha and cAMP signaling mediate plasmodium sporozoite apical regulated exocytosis and hepatocyte infection. *PLoS Pathog* 4:e1000008. <http://dx.doi.org/10.1371/journal.ppat.1000008>.
9. Conti M, Beavo J. 2007. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. *Annu Rev Biochem* 76:481–511. <http://dx.doi.org/10.1146/annurev.biochem.76.060305.150444>.
10. Beghyn TB, Charton J, Leroux F, Henninot A, Reboule I, Cos P, Maes L, Deprez B. 2012. Drug-to-genome-to-drug, step 2: reversing selectivity in a series of antiplasmodial compounds. *J Med Chem* 55:1274–1286. <http://dx.doi.org/10.1021/jm201422e>.
11. Beghyn TB, Charton J, Leroux F, Laconde G, Bourin A, Cos P, Maes L, Deprez B. 2011. Drug to genome to drug: discovery of new antiplasmodial compounds. *J Med Chem* 54:3222–3240. <http://dx.doi.org/10.1021/jm1014617>.
12. Martin SK, Miller LH, Nijhout MM, Carter R. 1978. Plasmodium gallinaceum: induction of male gametocyte eflagellation by phosphodiesterase inhibitors. *Exp Parasitol* 44:239–242. [http://dx.doi.org/10.1016/0014-4894\(78\)90104-2](http://dx.doi.org/10.1016/0014-4894(78)90104-2).
13. Trager W, Gill GS. 1989. Plasmodium falciparum gametocyte formation in vitro: its stimulation by phorbol diesters and by 8-bromo cyclic aden-

- osine monophosphate. *J Protozool* 36:451–454. <http://dx.doi.org/10.1111/j.1550-7408.1989.tb01079.x>.
14. Beraldo FH, Almeida FM, da Silva AM, Garcia CR. 2005. Cyclic AMP and calcium interplay as second messengers in melatonin-dependent regulation of *Plasmodium falciparum* cell cycle. *J Cell Biol* 170:551–557. <http://dx.doi.org/10.1083/jcb.200505117>.
  15. Moon RW, Taylor CJ, Bex C, Schepers R, Goulding D, Janse CJ, Waters AP, Baker DA, Billker O. 2009. A cyclic GMP signalling module that regulates gliding motility in a malaria parasite. *PLoS Pathog* 5:e1000599. <http://dx.doi.org/10.1371/journal.ppat.1000599>.
  16. Charbonneau H, Beier N, Walsh KA, Beavo JA. 1986. Identification of a conserved domain among cyclic nucleotide phosphodiesterases from diverse species. *Proc Natl Acad Sci U S A* 83:9308–9312. <http://dx.doi.org/10.1073/pnas.83.24.9308>.
  17. Kennedy M, Fishbaugher ME, Vaughan AM, Patrapuvich R, Boonhok R, Yimamnuaychok N, Rezakhani N, Metzger P, Ponpuak M, Sattabongkot J, Kappe SH, Hume JC, Lindner SE. 2012. A rapid and scalable density gradient purification method for *Plasmodium* sporozoites. *Malar J* 11:421. <http://dx.doi.org/10.1186/1475-2875-11-421>.
  18. Kawamoto F, Alejo-Blanco R, Fleck SL, Kawamoto Y, Sinden RE. 1990. Possible roles of Ca<sup>2+</sup> and cGMP as mediators of the exflagellation of *Plasmodium berghei* and *Plasmodium falciparum*. *Mol Biochem Parasitol* 42:101–108. [http://dx.doi.org/10.1016/0166-6851\(90\)90117-5](http://dx.doi.org/10.1016/0166-6851(90)90117-5).
  19. Collins CR, Hackett F, Strath M, Penzo M, Withers-Martinez C, Baker DA, Blackman MJ. 2013. Malaria parasite cGMP-dependent protein kinase regulates blood stage merozoite secretory organelle discharge and egress. *PLoS Pathog* 9:e1003344. <http://dx.doi.org/10.1371/journal.ppat.1003344>.
  20. Lindner SE, Mikolajczak SA, Vaughan AM, Moon W, Joyce BR, Sullivan WJ, Jr., Kappe SH. 2013. Perturbations of *Plasmodium* Puf2 expression and RNA-seq of Puf2-deficient sporozoites reveal a critical role in maintaining RNA homeostasis and parasite transmissibility. *Cell Microbiol* 15:1266–1283. <http://dx.doi.org/10.1111/cmi.12116>.
  21. Taylor CJ, McRobert L, Baker DA. 2008. Disruption of a *Plasmodium falciparum* cyclic nucleotide phosphodiesterase gene causes aberrant gametogenesis. *Mol Microbiol* 69:110–118. <http://dx.doi.org/10.1111/j.1365-2958.2008.06267.x>.
  22. Wentzinger L, Bopp S, Tenor H, Klar J, Brun R, Beck HP, Seebeck T. 2008. Cyclic nucleotide-specific phosphodiesterases of *Plasmodium falciparum*: PfPDEalpha, a non-essential cGMP-specific PDE that is an integral membrane protein. *Int J Parasitol* 38:1625–1637. <http://dx.doi.org/10.1016/j.ijpara.2008.05.016>.
  23. Sultan AA, Thathy V, Frevert U, Robson KJ, Crisanti A, Nussenzweig V, Nussenzweig RS, Ménard R. 1997. TRAP is necessary for gliding motility and infectivity of *Plasmodium* sporozoites. *Cell* 90:511–522. [http://dx.doi.org/10.1016/S0092-8674\(00\)80511-5](http://dx.doi.org/10.1016/S0092-8674(00)80511-5).
  24. Howard BL, Thompson PE, Manallack DT. 2011. Active site similarity between human and *Plasmodium falciparum* phosphodiesterases: considerations for antimalarial drug design. *J Comput Aided Mol Des* 25:753–762. <http://dx.doi.org/10.1007/s10822-011-9458-5>.
  25. Hopp CS, Bowyer PW, Baker DA. 2012. The role of cGMP signalling in regulating life cycle progression of *Plasmodium*. *Microbes Infect* 14:831–837. <http://dx.doi.org/10.1016/j.micinf.2012.04.011>.
  26. Pilz RB, Broderick KE. 2005. Role of cyclic GMP in gene regulation. *Front Biosci* 10:1239–1268. <http://dx.doi.org/10.2741/1616>.
  27. Bastian R, Dawe A, Meier S, Ludidi N, Bajic VB, Gehring C. 2010. Gibberellic acid and cGMP-dependent transcriptional regulation in *Ara-*bidopsis thaliana. *Plant Signal Behav* 5:224–232. <http://dx.doi.org/10.4161/psb.5.3.10718>.
  28. Gancedo JM. 2013. Biological roles of cAMP: variations on a theme in the different kingdoms of life. *Biol Rev Camb Philos Soc* 88:645–668. <http://dx.doi.org/10.1111/brv.12020>.
  29. Montagna GN, Matuschewski K, Buscaglia CA. 2012. *Plasmodium* sporozoite motility: an update. *Front Biosci* 17:726–744. <http://dx.doi.org/10.2741/3954>.
  30. Mueller AK, Camargo N, Kaiser K, Andorfer C, Frevert U, Matuschewski K, Kappe SH. 2005. *Plasmodium* liver stage developmental arrest by depletion of a protein at the parasite-host interface. *Proc Natl Acad Sci U S A* 102:3022–3027. <http://dx.doi.org/10.1073/pnas.0408442102>.
  31. Gomes-Santos CS, Braks J, Prudêncio M, Carret C, Gomes AR, Pain A, Feltwell T, Khan S, Waters A, Janse C, Mair GR, Mota MM. 2011. Transition of *Plasmodium* sporozoites into liver stage-like forms is regulated by the RNA binding protein Pumilio. *PLoS Pathog* 7:e1002046. <http://dx.doi.org/10.1371/journal.ppat.1002046>.
  32. Aly AS, Lindner SE, MacKellar DC, Peng X, Kappe SH. 2011. SAP1 is a critical post-transcriptional regulator of infectivity in malaria parasite sporozoite stages. *Mol Microbiol* 79:929–939. <http://dx.doi.org/10.1111/j.1365-2958.2010.07497.x>.
  33. Mikolajczak SA, Aly AS, Dumpit RF, Vaughan AM, Kappe SH. 2008. An efficient strategy for gene targeting and phenotypic assessment in the *Plasmodium yoelii* rodent malaria model. *Mol Biochem Parasitol* 158:213–216. <http://dx.doi.org/10.1016/j.molbiopara.2007.12.006>.
  34. Jongco AM, Ting LM, Thathy V, Mota MM, Kim K. 2006. Improved transfection and new selectable markers for the rodent malaria parasite *Plasmodium yoelii*. *Mol Biochem Parasitol* 146:242–250. <http://dx.doi.org/10.1016/j.molbiopara.2006.01.001>.
  35. Vignali M, Armour CD, Chen J, Morrison R, Castle JC, Biery MC, Bouzek H, Moon W, Babak T, Fried M, Raymond CK, Duffy PE. 2011. NSR-seq transcriptional profiling enables identification of a gene signature of *Plasmodium falciparum* parasites infecting children. *J Clin Invest* 121:1119–1129. <http://dx.doi.org/10.1172/JCI43457>.
  36. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with bowtie 2. *Nat Methods* 9:357–359. <http://dx.doi.org/10.1038/nmeth.1923>.
  37. Wold B, Myers RM. 2008. Sequence census methods for functional genomics. *Nat Methods* 5:19–21. <http://dx.doi.org/10.1038/nmeth1157>.
  38. Breitling R, Armengaud P, Amtmann A, Herzyk P. 2004. Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. *FEBS Lett* 573:83–92. <http://dx.doi.org/10.1016/j.febslet.2004.07.055>.
  39. Tusher VG, Tibshirani R, Chu G. 2001. Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci U S A* 98:5116–5121. <http://dx.doi.org/10.1073/pnas.091062498>.
  40. Robinson MD, Smyth GK. 2008. Small-sample estimation of negative binomial dispersion, with applications to SAGE data. *Biostatistics* 9:321–332. <http://dx.doi.org/10.1093/biostatistics/kxm030>.
  41. Anders S, Huber W. 2010. Differential expression analysis for sequence count data. *Genome Biol* 11:R106. <http://dx.doi.org/10.1186/gb-2010-11-10-r106>.
  42. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC. <http://www.ncbi.nlm.nih.gov/books/NBK54050/>.